N. Bandyopadhyay

发表

JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies

R. Salgia, Melissa L. Johnson, R. Knoblauch, 2020, JTO clinical and research reports.

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

K. Bevans, N. Agarwal, D. Ye, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-standard asymptotics in an inhomogeneous gamma process

Ananda Sen, N. Bandyopadhyay, 2005 .

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

C. Drake, E. Antonarakis, D. McNeel, 2019, Prostate Cancer and Prostatic Diseases.

Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation

Melissa L. Johnson, E. Haura, P. Cassier, 2022, The oncologist.

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Nibedita Bandyopadhyay, Martin Dreyling, Mathias Witzens-Harig, 2016, The Lancet.

Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

K. Bevans, N. Agarwal, D. Ye, 2021 .

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

P. Ascierto, R. Plummer, E. Felip, 2022, Cancer Chemotherapy and Pharmacology.

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

J. Friedberg, I. Flinn, Y. Oki, 2014, The Lancet. Oncology.

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

T. Plesner, H. Nahi, A. Oriol, 2023, Leukemia & lymphoma.

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer.

N. Agarwal, E. Attiyeh, A. Hansen, 2023, Clinical genitourinary cancer.

‘The Green Sleuth’: An Analysis of the Environmentalism in the Selected Detective Fictions of Sunil Gangopadhyay

N. Bandyopadhyay, 2018 .

Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 bispecific antibody, for the treatment of metastatic castrate-resistant prostate cancer (mCRPC).

N. Agarwal, E. Attiyeh, A. Hansen, 2022, Journal of Clinical Oncology.

Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study.

A. Baruchel, D. Teachey, N. Shukla, 2022, Journal of Clinical Oncology.

P360: EFFICACY AND SAFETY OF DARATUMUMAB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA OR LYMPHOBLASTIC LYMPHOMA: RESULTS FROM PHASE 2 DELPHINUS STUDY

A. Baruchel, D. Teachey, A. Vora, 2022, HemaSphere.

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

J. Goldberg, M. Jerkeman, M. Dreyling, 2016, The Lancet.

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer

C. Drake, E. Antonarakis, D. McNeel, 2021, Prostate Cancer and Prostatic Diseases.

Digital Commons

N. Bandyopadhyay, Hong Xie, D. Cortinovis, 2022 .